Balancing Cancer Treatment and Heart Health: Linamaria’s Story – Oncogene Cancer Research
Oncogene Cancer Research shared a post on LinkedIn:
“Did you know that some cancer drugs can cause heart issues which are known as cardiotoxicity?
Linamaria, from Colombia, learned this after starting her targeted therapy for her ALK+ lung cancer.
Linamaria had always been healthy and was diagnosed in August 2023. While she was initially told her lung cancer was inoperable, her team revised their opinion after seeing that Lina’s lung cancer had shrunk by 80% on her targeted therapy.
After recovery from surgery, Linamaria learned she had developed bradycardia – the slowing of the heart which can become serious. Her symptoms? She began feeling dizzy, tired and her feet would swell up like balloons. She also noted she had low blood pressure.
Thankfully, so far, Linamaria has not required any further medication and manages the feet swelling with compression socks. She’s also grateful to know of the cardiotoxicity risks and to be monitored by her team.
Let’s support Linamaria and create more awareness of cardiology issues relating to cancer treatment. Cancer patients should not have to choose between taking their cancer meds or protecting their hearts.”
More posts featuring Oncogene Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023